Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031
According to our (Global Info Research) latest study, the global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases market size was valued at US$ million in 2024 and is forecast to a readjusted size of USD million by 2031 with a CAGR of %during review period.
This report is a detailed and comprehensive analysis for global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AbaStar MDx, Abbott Laboratories, Abiant, Acumen Pharmaceuticals, Alseres Pharmaceuticals, Athena Diagnostics, Banyan Biomarkers, Bio-Rad Laboratories, Diagenic ASA, Immunarray Pvt, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases, with price, sales quantity, revenue, and global market share of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases from 2020 to 2025.
Chapter 3, the Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases.
Chapter 14 and 15, to describe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases sales channel, distributors, customers, research findings and conclusion.
This report is a detailed and comprehensive analysis for global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AbaStar MDx, Abbott Laboratories, Abiant, Acumen Pharmaceuticals, Alseres Pharmaceuticals, Athena Diagnostics, Banyan Biomarkers, Bio-Rad Laboratories, Diagenic ASA, Immunarray Pvt, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Genome
- Proteome
- Hospital Laboratories
- Research Organizations
- Others
- AbaStar MDx
- Abbott Laboratories
- Abiant
- Acumen Pharmaceuticals
- Alseres Pharmaceuticals
- Athena Diagnostics
- Banyan Biomarkers
- Bio-Rad Laboratories
- Diagenic ASA
- Immunarray Pvt
- Myriad RBM
- Proteome Sciences
- ProteoSys AG
- Psynova Neurotech
- Qiagen
- Quanterix Corporation
- Thermo Fisher Scientific
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases, with price, sales quantity, revenue, and global market share of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases from 2020 to 2025.
Chapter 3, the Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases.
Chapter 14 and 15, to describe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases sales channel, distributors, customers, research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Type: 2020 Versus 2024 Versus 2031
1.3.2 Genome
1.3.3 Proteome
1.4 Market Analysis by Application
1.4.1 Overview: Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Application: 2020 Versus 2024 Versus 2031
1.4.2 Hospital Laboratories
1.4.3 Research Organizations
1.4.4 Others
1.5 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size & Forecast
1.5.1 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020 & 2024 & 2031)
1.5.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity (2020-2031)
1.5.3 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Average Price (2020-2031)
2 MANUFACTURERS PROFILES
2.1 AbaStar MDx
2.1.1 AbaStar MDx Details
2.1.2 AbaStar MDx Major Business
2.1.3 AbaStar MDx Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
2.1.4 AbaStar MDx Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.1.5 AbaStar MDx Recent Developments/Updates
2.2 Abbott Laboratories
2.2.1 Abbott Laboratories Details
2.2.2 Abbott Laboratories Major Business
2.2.3 Abbott Laboratories Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
2.2.4 Abbott Laboratories Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.2.5 Abbott Laboratories Recent Developments/Updates
2.3 Abiant
2.3.1 Abiant Details
2.3.2 Abiant Major Business
2.3.3 Abiant Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
2.3.4 Abiant Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.3.5 Abiant Recent Developments/Updates
2.4 Acumen Pharmaceuticals
2.4.1 Acumen Pharmaceuticals Details
2.4.2 Acumen Pharmaceuticals Major Business
2.4.3 Acumen Pharmaceuticals Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
2.4.4 Acumen Pharmaceuticals Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.4.5 Acumen Pharmaceuticals Recent Developments/Updates
2.5 Alseres Pharmaceuticals
2.5.1 Alseres Pharmaceuticals Details
2.5.2 Alseres Pharmaceuticals Major Business
2.5.3 Alseres Pharmaceuticals Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
2.5.4 Alseres Pharmaceuticals Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.5.5 Alseres Pharmaceuticals Recent Developments/Updates
2.6 Athena Diagnostics
2.6.1 Athena Diagnostics Details
2.6.2 Athena Diagnostics Major Business
2.6.3 Athena Diagnostics Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
2.6.4 Athena Diagnostics Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.6.5 Athena Diagnostics Recent Developments/Updates
2.7 Banyan Biomarkers
2.7.1 Banyan Biomarkers Details
2.7.2 Banyan Biomarkers Major Business
2.7.3 Banyan Biomarkers Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
2.7.4 Banyan Biomarkers Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.7.5 Banyan Biomarkers Recent Developments/Updates
2.8 Bio-Rad Laboratories
2.8.1 Bio-Rad Laboratories Details
2.8.2 Bio-Rad Laboratories Major Business
2.8.3 Bio-Rad Laboratories Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
2.8.4 Bio-Rad Laboratories Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.8.5 Bio-Rad Laboratories Recent Developments/Updates
2.9 Diagenic ASA
2.9.1 Diagenic ASA Details
2.9.2 Diagenic ASA Major Business
2.9.3 Diagenic ASA Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
2.9.4 Diagenic ASA Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.9.5 Diagenic ASA Recent Developments/Updates
2.10 Immunarray Pvt
2.10.1 Immunarray Pvt Details
2.10.2 Immunarray Pvt Major Business
2.10.3 Immunarray Pvt Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
2.10.4 Immunarray Pvt Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.10.5 Immunarray Pvt Recent Developments/Updates
2.11 Myriad RBM
2.11.1 Myriad RBM Details
2.11.2 Myriad RBM Major Business
2.11.3 Myriad RBM Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
2.11.4 Myriad RBM Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.11.5 Myriad RBM Recent Developments/Updates
2.12 Proteome Sciences
2.12.1 Proteome Sciences Details
2.12.2 Proteome Sciences Major Business
2.12.3 Proteome Sciences Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
2.12.4 Proteome Sciences Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.12.5 Proteome Sciences Recent Developments/Updates
2.13 ProteoSys AG
2.13.1 ProteoSys AG Details
2.13.2 ProteoSys AG Major Business
2.13.3 ProteoSys AG Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
2.13.4 ProteoSys AG Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.13.5 ProteoSys AG Recent Developments/Updates
2.14 Psynova Neurotech
2.14.1 Psynova Neurotech Details
2.14.2 Psynova Neurotech Major Business
2.14.3 Psynova Neurotech Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
2.14.4 Psynova Neurotech Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.14.5 Psynova Neurotech Recent Developments/Updates
2.15 Qiagen
2.15.1 Qiagen Details
2.15.2 Qiagen Major Business
2.15.3 Qiagen Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
2.15.4 Qiagen Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.15.5 Qiagen Recent Developments/Updates
2.16 Quanterix Corporation
2.16.1 Quanterix Corporation Details
2.16.2 Quanterix Corporation Major Business
2.16.3 Quanterix Corporation Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
2.16.4 Quanterix Corporation Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.16.5 Quanterix Corporation Recent Developments/Updates
2.17 Thermo Fisher Scientific
2.17.1 Thermo Fisher Scientific Details
2.17.2 Thermo Fisher Scientific Major Business
2.17.3 Thermo Fisher Scientific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
2.17.4 Thermo Fisher Scientific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.17.5 Thermo Fisher Scientific Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: NEUROLOGICAL BIOMARKERS FOR ALZHEIMER`S AND PARKINSON`S DISEASES BY MANUFACTURER
3.1 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Manufacturer (2020-2025)
3.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue by Manufacturer (2020-2025)
3.3 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Average Price by Manufacturer (2020-2025)
3.4 Market Share Analysis (2024)
3.4.1 Producer Shipments of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases by Manufacturer Revenue ($MM) and Market Share (%): 2024
3.4.2 Top 3 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Manufacturer Market Share in 2024
3.4.3 Top 6 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Manufacturer Market Share in 2024
3.5 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market: Overall Company Footprint Analysis
3.5.1 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market: Region Footprint
3.5.2 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market: Company Product Type Footprint
3.5.3 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Region
4.1.1 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Region (2020-2031)
4.1.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Region (2020-2031)
4.1.3 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Average Price by Region (2020-2031)
4.2 North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031)
4.3 Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031)
4.4 Asia-Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031)
4.5 South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031)
4.6 Middle East & Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031)
5 MARKET SEGMENT BY TYPE
5.1 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Type (2020-2031)
5.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Type (2020-2031)
5.3 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Average Price by Type (2020-2031)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Application (2020-2031)
6.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Application (2020-2031)
6.3 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Average Price by Application (2020-2031)
7 NORTH AMERICA
7.1 North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Type (2020-2031)
7.2 North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Application (2020-2031)
7.3 North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Country
7.3.1 North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Country (2020-2031)
7.3.2 North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Country (2020-2031)
7.3.3 United States Market Size and Forecast (2020-2031)
7.3.4 Canada Market Size and Forecast (2020-2031)
7.3.5 Mexico Market Size and Forecast (2020-2031)
8 EUROPE
8.1 Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Type (2020-2031)
8.2 Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Application (2020-2031)
8.3 Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Country
8.3.1 Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Country (2020-2031)
8.3.2 Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Country (2020-2031)
8.3.3 Germany Market Size and Forecast (2020-2031)
8.3.4 France Market Size and Forecast (2020-2031)
8.3.5 United Kingdom Market Size and Forecast (2020-2031)
8.3.6 Russia Market Size and Forecast (2020-2031)
8.3.7 Italy Market Size and Forecast (2020-2031)
9 ASIA-PACIFIC
9.1 Asia-Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Type (2020-2031)
9.2 Asia-Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Application (2020-2031)
9.3 Asia-Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Region
9.3.1 Asia-Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Region (2020-2031)
9.3.2 Asia-Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Region (2020-2031)
9.3.3 China Market Size and Forecast (2020-2031)
9.3.4 Japan Market Size and Forecast (2020-2031)
9.3.5 South Korea Market Size and Forecast (2020-2031)
9.3.6 India Market Size and Forecast (2020-2031)
9.3.7 Southeast Asia Market Size and Forecast (2020-2031)
9.3.8 Australia Market Size and Forecast (2020-2031)
10 SOUTH AMERICA
10.1 South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Type (2020-2031)
10.2 South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Application (2020-2031)
10.3 South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Country
10.3.1 South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Country (2020-2031)
10.3.2 South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Country (2020-2031)
10.3.3 Brazil Market Size and Forecast (2020-2031)
10.3.4 Argentina Market Size and Forecast (2020-2031)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Type (2020-2031)
11.2 Middle East & Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Application (2020-2031)
11.3 Middle East & Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Country
11.3.1 Middle East & Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Country (2020-2031)
11.3.2 Middle East & Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Country (2020-2031)
11.3.3 Turkey Market Size and Forecast (2020-2031)
11.3.4 Egypt Market Size and Forecast (2020-2031)
11.3.5 Saudi Arabia Market Size and Forecast (2020-2031)
11.3.6 South Africa Market Size and Forecast (2020-2031)
12 MARKET DYNAMICS
12.1 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Drivers
12.2 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Restraints
12.3 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases and Key Manufacturers
13.2 Manufacturing Costs Percentage of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases
13.3 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production Process
13.4 Industry Value Chain Analysis
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Typical Distributors
14.3 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Type: 2020 Versus 2024 Versus 2031
1.3.2 Genome
1.3.3 Proteome
1.4 Market Analysis by Application
1.4.1 Overview: Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Application: 2020 Versus 2024 Versus 2031
1.4.2 Hospital Laboratories
1.4.3 Research Organizations
1.4.4 Others
1.5 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size & Forecast
1.5.1 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020 & 2024 & 2031)
1.5.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity (2020-2031)
1.5.3 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Average Price (2020-2031)
2 MANUFACTURERS PROFILES
2.1 AbaStar MDx
2.1.1 AbaStar MDx Details
2.1.2 AbaStar MDx Major Business
2.1.3 AbaStar MDx Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
2.1.4 AbaStar MDx Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.1.5 AbaStar MDx Recent Developments/Updates
2.2 Abbott Laboratories
2.2.1 Abbott Laboratories Details
2.2.2 Abbott Laboratories Major Business
2.2.3 Abbott Laboratories Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
2.2.4 Abbott Laboratories Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.2.5 Abbott Laboratories Recent Developments/Updates
2.3 Abiant
2.3.1 Abiant Details
2.3.2 Abiant Major Business
2.3.3 Abiant Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
2.3.4 Abiant Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.3.5 Abiant Recent Developments/Updates
2.4 Acumen Pharmaceuticals
2.4.1 Acumen Pharmaceuticals Details
2.4.2 Acumen Pharmaceuticals Major Business
2.4.3 Acumen Pharmaceuticals Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
2.4.4 Acumen Pharmaceuticals Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.4.5 Acumen Pharmaceuticals Recent Developments/Updates
2.5 Alseres Pharmaceuticals
2.5.1 Alseres Pharmaceuticals Details
2.5.2 Alseres Pharmaceuticals Major Business
2.5.3 Alseres Pharmaceuticals Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
2.5.4 Alseres Pharmaceuticals Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.5.5 Alseres Pharmaceuticals Recent Developments/Updates
2.6 Athena Diagnostics
2.6.1 Athena Diagnostics Details
2.6.2 Athena Diagnostics Major Business
2.6.3 Athena Diagnostics Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
2.6.4 Athena Diagnostics Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.6.5 Athena Diagnostics Recent Developments/Updates
2.7 Banyan Biomarkers
2.7.1 Banyan Biomarkers Details
2.7.2 Banyan Biomarkers Major Business
2.7.3 Banyan Biomarkers Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
2.7.4 Banyan Biomarkers Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.7.5 Banyan Biomarkers Recent Developments/Updates
2.8 Bio-Rad Laboratories
2.8.1 Bio-Rad Laboratories Details
2.8.2 Bio-Rad Laboratories Major Business
2.8.3 Bio-Rad Laboratories Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
2.8.4 Bio-Rad Laboratories Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.8.5 Bio-Rad Laboratories Recent Developments/Updates
2.9 Diagenic ASA
2.9.1 Diagenic ASA Details
2.9.2 Diagenic ASA Major Business
2.9.3 Diagenic ASA Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
2.9.4 Diagenic ASA Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.9.5 Diagenic ASA Recent Developments/Updates
2.10 Immunarray Pvt
2.10.1 Immunarray Pvt Details
2.10.2 Immunarray Pvt Major Business
2.10.3 Immunarray Pvt Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
2.10.4 Immunarray Pvt Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.10.5 Immunarray Pvt Recent Developments/Updates
2.11 Myriad RBM
2.11.1 Myriad RBM Details
2.11.2 Myriad RBM Major Business
2.11.3 Myriad RBM Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
2.11.4 Myriad RBM Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.11.5 Myriad RBM Recent Developments/Updates
2.12 Proteome Sciences
2.12.1 Proteome Sciences Details
2.12.2 Proteome Sciences Major Business
2.12.3 Proteome Sciences Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
2.12.4 Proteome Sciences Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.12.5 Proteome Sciences Recent Developments/Updates
2.13 ProteoSys AG
2.13.1 ProteoSys AG Details
2.13.2 ProteoSys AG Major Business
2.13.3 ProteoSys AG Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
2.13.4 ProteoSys AG Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.13.5 ProteoSys AG Recent Developments/Updates
2.14 Psynova Neurotech
2.14.1 Psynova Neurotech Details
2.14.2 Psynova Neurotech Major Business
2.14.3 Psynova Neurotech Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
2.14.4 Psynova Neurotech Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.14.5 Psynova Neurotech Recent Developments/Updates
2.15 Qiagen
2.15.1 Qiagen Details
2.15.2 Qiagen Major Business
2.15.3 Qiagen Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
2.15.4 Qiagen Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.15.5 Qiagen Recent Developments/Updates
2.16 Quanterix Corporation
2.16.1 Quanterix Corporation Details
2.16.2 Quanterix Corporation Major Business
2.16.3 Quanterix Corporation Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
2.16.4 Quanterix Corporation Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.16.5 Quanterix Corporation Recent Developments/Updates
2.17 Thermo Fisher Scientific
2.17.1 Thermo Fisher Scientific Details
2.17.2 Thermo Fisher Scientific Major Business
2.17.3 Thermo Fisher Scientific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
2.17.4 Thermo Fisher Scientific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.17.5 Thermo Fisher Scientific Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: NEUROLOGICAL BIOMARKERS FOR ALZHEIMER`S AND PARKINSON`S DISEASES BY MANUFACTURER
3.1 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Manufacturer (2020-2025)
3.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue by Manufacturer (2020-2025)
3.3 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Average Price by Manufacturer (2020-2025)
3.4 Market Share Analysis (2024)
3.4.1 Producer Shipments of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases by Manufacturer Revenue ($MM) and Market Share (%): 2024
3.4.2 Top 3 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Manufacturer Market Share in 2024
3.4.3 Top 6 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Manufacturer Market Share in 2024
3.5 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market: Overall Company Footprint Analysis
3.5.1 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market: Region Footprint
3.5.2 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market: Company Product Type Footprint
3.5.3 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Region
4.1.1 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Region (2020-2031)
4.1.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Region (2020-2031)
4.1.3 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Average Price by Region (2020-2031)
4.2 North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031)
4.3 Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031)
4.4 Asia-Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031)
4.5 South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031)
4.6 Middle East & Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031)
5 MARKET SEGMENT BY TYPE
5.1 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Type (2020-2031)
5.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Type (2020-2031)
5.3 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Average Price by Type (2020-2031)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Application (2020-2031)
6.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Application (2020-2031)
6.3 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Average Price by Application (2020-2031)
7 NORTH AMERICA
7.1 North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Type (2020-2031)
7.2 North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Application (2020-2031)
7.3 North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Country
7.3.1 North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Country (2020-2031)
7.3.2 North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Country (2020-2031)
7.3.3 United States Market Size and Forecast (2020-2031)
7.3.4 Canada Market Size and Forecast (2020-2031)
7.3.5 Mexico Market Size and Forecast (2020-2031)
8 EUROPE
8.1 Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Type (2020-2031)
8.2 Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Application (2020-2031)
8.3 Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Country
8.3.1 Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Country (2020-2031)
8.3.2 Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Country (2020-2031)
8.3.3 Germany Market Size and Forecast (2020-2031)
8.3.4 France Market Size and Forecast (2020-2031)
8.3.5 United Kingdom Market Size and Forecast (2020-2031)
8.3.6 Russia Market Size and Forecast (2020-2031)
8.3.7 Italy Market Size and Forecast (2020-2031)
9 ASIA-PACIFIC
9.1 Asia-Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Type (2020-2031)
9.2 Asia-Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Application (2020-2031)
9.3 Asia-Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Region
9.3.1 Asia-Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Region (2020-2031)
9.3.2 Asia-Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Region (2020-2031)
9.3.3 China Market Size and Forecast (2020-2031)
9.3.4 Japan Market Size and Forecast (2020-2031)
9.3.5 South Korea Market Size and Forecast (2020-2031)
9.3.6 India Market Size and Forecast (2020-2031)
9.3.7 Southeast Asia Market Size and Forecast (2020-2031)
9.3.8 Australia Market Size and Forecast (2020-2031)
10 SOUTH AMERICA
10.1 South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Type (2020-2031)
10.2 South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Application (2020-2031)
10.3 South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Country
10.3.1 South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Country (2020-2031)
10.3.2 South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Country (2020-2031)
10.3.3 Brazil Market Size and Forecast (2020-2031)
10.3.4 Argentina Market Size and Forecast (2020-2031)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Type (2020-2031)
11.2 Middle East & Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Application (2020-2031)
11.3 Middle East & Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Country
11.3.1 Middle East & Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Country (2020-2031)
11.3.2 Middle East & Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Country (2020-2031)
11.3.3 Turkey Market Size and Forecast (2020-2031)
11.3.4 Egypt Market Size and Forecast (2020-2031)
11.3.5 Saudi Arabia Market Size and Forecast (2020-2031)
11.3.6 South Africa Market Size and Forecast (2020-2031)
12 MARKET DYNAMICS
12.1 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Drivers
12.2 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Restraints
12.3 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases and Key Manufacturers
13.2 Manufacturing Costs Percentage of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases
13.3 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production Process
13.4 Industry Value Chain Analysis
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Typical Distributors
14.3 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
LIST OF FIGURES
Table 1. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Type, (USD Million), 2020 & 2024 & 2031
Table 2. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
Table 3. AbaStar MDx Basic Information, Manufacturing Base and Competitors
Table 4. AbaStar MDx Major Business
Table 5. AbaStar MDx Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
Table 6. AbaStar MDx Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 7. AbaStar MDx Recent Developments/Updates
Table 8. Abbott Laboratories Basic Information, Manufacturing Base and Competitors
Table 9. Abbott Laboratories Major Business
Table 10. Abbott Laboratories Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
Table 11. Abbott Laboratories Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 12. Abbott Laboratories Recent Developments/Updates
Table 13. Abiant Basic Information, Manufacturing Base and Competitors
Table 14. Abiant Major Business
Table 15. Abiant Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
Table 16. Abiant Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 17. Abiant Recent Developments/Updates
Table 18. Acumen Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 19. Acumen Pharmaceuticals Major Business
Table 20. Acumen Pharmaceuticals Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
Table 21. Acumen Pharmaceuticals Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 22. Acumen Pharmaceuticals Recent Developments/Updates
Table 23. Alseres Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 24. Alseres Pharmaceuticals Major Business
Table 25. Alseres Pharmaceuticals Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
Table 26. Alseres Pharmaceuticals Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 27. Alseres Pharmaceuticals Recent Developments/Updates
Table 28. Athena Diagnostics Basic Information, Manufacturing Base and Competitors
Table 29. Athena Diagnostics Major Business
Table 30. Athena Diagnostics Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
Table 31. Athena Diagnostics Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 32. Athena Diagnostics Recent Developments/Updates
Table 33. Banyan Biomarkers Basic Information, Manufacturing Base and Competitors
Table 34. Banyan Biomarkers Major Business
Table 35. Banyan Biomarkers Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
Table 36. Banyan Biomarkers Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 37. Banyan Biomarkers Recent Developments/Updates
Table 38. Bio-Rad Laboratories Basic Information, Manufacturing Base and Competitors
Table 39. Bio-Rad Laboratories Major Business
Table 40. Bio-Rad Laboratories Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
Table 41. Bio-Rad Laboratories Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 42. Bio-Rad Laboratories Recent Developments/Updates
Table 43. Diagenic ASA Basic Information, Manufacturing Base and Competitors
Table 44. Diagenic ASA Major Business
Table 45. Diagenic ASA Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
Table 46. Diagenic ASA Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 47. Diagenic ASA Recent Developments/Updates
Table 48. Immunarray Pvt Basic Information, Manufacturing Base and Competitors
Table 49. Immunarray Pvt Major Business
Table 50. Immunarray Pvt Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
Table 51. Immunarray Pvt Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 52. Immunarray Pvt Recent Developments/Updates
Table 53. Myriad RBM Basic Information, Manufacturing Base and Competitors
Table 54. Myriad RBM Major Business
Table 55. Myriad RBM Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
Table 56. Myriad RBM Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 57. Myriad RBM Recent Developments/Updates
Table 58. Proteome Sciences Basic Information, Manufacturing Base and Competitors
Table 59. Proteome Sciences Major Business
Table 60. Proteome Sciences Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
Table 61. Proteome Sciences Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 62. Proteome Sciences Recent Developments/Updates
Table 63. ProteoSys AG Basic Information, Manufacturing Base and Competitors
Table 64. ProteoSys AG Major Business
Table 65. ProteoSys AG Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
Table 66. ProteoSys AG Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 67. ProteoSys AG Recent Developments/Updates
Table 68. Psynova Neurotech Basic Information, Manufacturing Base and Competitors
Table 69. Psynova Neurotech Major Business
Table 70. Psynova Neurotech Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
Table 71. Psynova Neurotech Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 72. Psynova Neurotech Recent Developments/Updates
Table 73. Qiagen Basic Information, Manufacturing Base and Competitors
Table 74. Qiagen Major Business
Table 75. Qiagen Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
Table 76. Qiagen Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 77. Qiagen Recent Developments/Updates
Table 78. Quanterix Corporation Basic Information, Manufacturing Base and Competitors
Table 79. Quanterix Corporation Major Business
Table 80. Quanterix Corporation Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
Table 81. Quanterix Corporation Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 82. Quanterix Corporation Recent Developments/Updates
Table 83. Thermo Fisher Scientific Basic Information, Manufacturing Base and Competitors
Table 84. Thermo Fisher Scientific Major Business
Table 85. Thermo Fisher Scientific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
Table 86. Thermo Fisher Scientific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 87. Thermo Fisher Scientific Recent Developments/Updates
Table 88. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Manufacturer (2020-2025) & (K Units)
Table 89. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue by Manufacturer (2020-2025) & (USD Million)
Table 90. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Average Price by Manufacturer (2020-2025) & (US$/Unit)
Table 91. Market Position of Manufacturers in Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2024
Table 92. Head Office and Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production Site of Key Manufacturer
Table 93. Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market: Company Product Type Footprint
Table 94. Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market: Company Product Application Footprint
Table 95. Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases New Market Entrants and Barriers to Market Entry
Table 96. Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Mergers, Acquisition, Agreements, and Collaborations
Table 97. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Region (2020-2024-2031) & (USD Million) & CAGR
Table 98. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Region (2020-2025) & (K Units)
Table 99. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Region (2026-2031) & (K Units)
Table 100. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Region (2020-2025) & (USD Million)
Table 101. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Region (2026-2031) & (USD Million)
Table 102. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Average Price by Region (2020-2025) & (US$/Unit)
Table 103. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Average Price by Region (2026-2031) & (US$/Unit)
Table 104. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Type (2020-2025) & (K Units)
Table 105. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Type (2026-2031) & (K Units)
Table 106. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Type (2020-2025) & (USD Million)
Table 107. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Type (2026-2031) & (USD Million)
Table 108. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Average Price by Type (2020-2025) & (US$/Unit)
Table 109. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Average Price by Type (2026-2031) & (US$/Unit)
Table 110. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Application (2020-2025) & (K Units)
Table 111. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Application (2026-2031) & (K Units)
Table 112. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Application (2020-2025) & (USD Million)
Table 113. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Application (2026-2031) & (USD Million)
Table 114. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Average Price by Application (2020-2025) & (US$/Unit)
Table 115. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Average Price by Application (2026-2031) & (US$/Unit)
Table 116. North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Type (2020-2025) & (K Units)
Table 117. North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Type (2026-2031) & (K Units)
Table 118. North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Application (2020-2025) & (K Units)
Table 119. North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Application (2026-2031) & (K Units)
Table 120. North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Country (2020-2025) & (K Units)
Table 121. North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Country (2026-2031) & (K Units)
Table 122. North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Country (2020-2025) & (USD Million)
Table 123. North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Country (2026-2031) & (USD Million)
Table 124. Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Type (2020-2025) & (K Units)
Table 125. Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Type (2026-2031) & (K Units)
Table 126. Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Application (2020-2025) & (K Units)
Table 127. Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Application (2026-2031) & (K Units)
Table 128. Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Country (2020-2025) & (K Units)
Table 129. Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Country (2026-2031) & (K Units)
Table 130. Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Country (2020-2025) & (USD Million)
Table 131. Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Country (2026-2031) & (USD Million)
Table 132. Asia-Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Type (2020-2025) & (K Units)
Table 133. Asia-Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Type (2026-2031) & (K Units)
Table 134. Asia-Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Application (2020-2025) & (K Units)
Table 135. Asia-Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Application (2026-2031) & (K Units)
Table 136. Asia-Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Region (2020-2025) & (K Units)
Table 137. Asia-Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Region (2026-2031) & (K Units)
Table 138. Asia-Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Region (2020-2025) & (USD Million)
Table 139. Asia-Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Region (2026-2031) & (USD Million)
Table 140. South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Type (2020-2025) & (K Units)
Table 141. South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Type (2026-2031) & (K Units)
Table 142. South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Application (2020-2025) & (K Units)
Table 143. South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Application (2026-2031) & (K Units)
Table 144. South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Country (2020-2025) & (K Units)
Table 145. South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Country (2026-2031) & (K Units)
Table 146. South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Country (2020-2025) & (USD Million)
Table 147. South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Country (2026-2031) & (USD Million)
Table 148. Middle East & Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Type (2020-2025) & (K Units)
Table 149. Middle East & Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Type (2026-2031) & (K Units)
Table 150. Middle East & Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Application (2020-2025) & (K Units)
Table 151. Middle East & Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Application (2026-2031) & (K Units)
Table 152. Middle East & Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Country (2020-2025) & (K Units)
Table 153. Middle East & Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Country (2026-2031) & (K Units)
Table 154. Middle East & Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Country (2020-2025) & (USD Million)
Table 155. Middle East & Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Country (2026-2031) & (USD Million)
Table 156. Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Raw Material
Table 157. Key Manufacturers of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Raw Materials
Table 158. Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Typical Distributors
Table 159. Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Typical Customers
LIST OF FIGURES
Figure 1. Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Picture
Figure 2. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue by Type, (USD Million), 2020 & 2024 & 2031
Figure 3. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Market Share by Type in 2024
Figure 4. Genome Examples
Figure 5. Proteome Examples
Figure 6. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
Figure 7. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Market Share by Application in 2024
Figure 8. Hospital Laboratories Examples
Figure 9. Research Organizations Examples
Figure 10. Others Examples
Figure 11. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value, (USD Million): 2020 & 2024 & 2031
Figure 12. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value and Forecast (2020-2031) & (USD Million)
Figure 13. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity (2020-2031) & (K Units)
Figure 14. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Price (2020-2031) & (US$/Unit)
Figure 15. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity Market Share by Manufacturer in 2024
Figure 16. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Market Share by Manufacturer in 2024
Figure 17. Producer Shipments of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases by Manufacturer Sales ($MM) and Market Share (%): 2024
Figure 18. Top 3 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Manufacturer (Revenue) Market Share in 2024
Figure 19. Top 6 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Manufacturer (Revenue) Market Share in 2024
Figure 20. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity Market Share by Region (2020-2031)
Figure 21. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value Market Share by Region (2020-2031)
Figure 22. North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031) & (USD Million)
Figure 23. Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031) & (USD Million)
Figure 24. Asia-Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031) & (USD Million)
Figure 25. South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031) & (USD Million)
Figure 26. Middle East & Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031) & (USD Million)
Figure 27. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity Market Share by Type (2020-2031)
Figure 28. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value Market Share by Type (2020-2031)
Figure 29. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Average Price by Type (2020-2031) & (US$/Unit)
Figure 30. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity Market Share by Application (2020-2031)
Figure 31. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Market Share by Application (2020-2031)
Figure 32. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Average Price by Application (2020-2031) & (US$/Unit)
Figure 33. North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity Market Share by Type (2020-2031)
Figure 34. North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity Market Share by Application (2020-2031)
Figure 35. North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity Market Share by Country (2020-2031)
Figure 36. North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value Market Share by Country (2020-2031)
Figure 37. United States Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031) & (USD Million)
Figure 38. Canada Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031) & (USD Million)
Figure 39. Mexico Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031) & (USD Million)
Figure 40. Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity Market Share by Type (2020-2031)
Figure 41. Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity Market Share by Application (2020-2031)
Figure 42. Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity Market Share by Country (2020-2031)
Figure 43. Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value Market Share by Country (2020-2031)
Figure 44. Germany Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031) & (USD Million)
Figure 45. France Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031) & (USD Million)
Figure 46. United Kingdom Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031) & (USD Million)
Figure 47. Russia Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031) & (USD Million)
Figure 48. Italy Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031) & (USD Million)
Figure 49. Asia-Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity Market Share by Type (2020-2031)
Figure 50. Asia-Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity Market Share by Application (2020-2031)
Figure 51. Asia-Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity Market Share by Region (2020-2031)
Figure 52. Asia-Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value Market Share by Region (2020-2031)
Figure 53. China Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031) & (USD Million)
Figure 54. Japan Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031) & (USD Million)
Figure 55. South Korea Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031) & (USD Million)
Figure 56. India Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031) & (USD Million)
Figure 57. Southeast Asia Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031) & (USD Million)
Figure 58. Australia Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031) & (USD Million)
Figure 59. South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity Market Share by Type (2020-2031)
Figure 60. South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity Market Share by Application (2020-2031)
Figure 61. South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity Market Share by Country (2020-2031)
Figure 62. South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value Market Share by Country (2020-2031)
Figure 63. Brazil Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031) & (USD Million)
Figure 64. Argentina Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031) & (USD Million)
Figure 65. Middle East & Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity Market Share by Type (2020-2031)
Figure 66. Middle East & Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity Market Share by Application (2020-2031)
Figure 67. Middle East & Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity Market Share by Country (2020-2031)
Figure 68. Middle East & Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value Market Share by Country (2020-2031)
Figure 69. Turkey Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031) & (USD Million)
Figure 70. Egypt Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031) & (USD Million)
Figure 71. Saudi Arabia Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031) & (USD Million)
Figure 72. South Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031) & (USD Million)
Figure 73. Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Drivers
Figure 74. Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Restraints
Figure 75. Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Trends
Figure 76. Porters Five Forces Analysis
Figure 77. Manufacturing Cost Structure Analysis of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases in 2024
Figure 78. Manufacturing Process Analysis of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases
Figure 79. Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Industrial Chain
Figure 80. Sales Channel: Direct to End-User vs Distributors
Figure 81. Direct Channel Pros & Cons
Figure 82. Indirect Channel Pros & Cons
Figure 83. Methodology
Figure 84. Research Process and Data Source
Table 1. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Type, (USD Million), 2020 & 2024 & 2031
Table 2. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
Table 3. AbaStar MDx Basic Information, Manufacturing Base and Competitors
Table 4. AbaStar MDx Major Business
Table 5. AbaStar MDx Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
Table 6. AbaStar MDx Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 7. AbaStar MDx Recent Developments/Updates
Table 8. Abbott Laboratories Basic Information, Manufacturing Base and Competitors
Table 9. Abbott Laboratories Major Business
Table 10. Abbott Laboratories Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
Table 11. Abbott Laboratories Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 12. Abbott Laboratories Recent Developments/Updates
Table 13. Abiant Basic Information, Manufacturing Base and Competitors
Table 14. Abiant Major Business
Table 15. Abiant Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
Table 16. Abiant Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 17. Abiant Recent Developments/Updates
Table 18. Acumen Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 19. Acumen Pharmaceuticals Major Business
Table 20. Acumen Pharmaceuticals Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
Table 21. Acumen Pharmaceuticals Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 22. Acumen Pharmaceuticals Recent Developments/Updates
Table 23. Alseres Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 24. Alseres Pharmaceuticals Major Business
Table 25. Alseres Pharmaceuticals Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
Table 26. Alseres Pharmaceuticals Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 27. Alseres Pharmaceuticals Recent Developments/Updates
Table 28. Athena Diagnostics Basic Information, Manufacturing Base and Competitors
Table 29. Athena Diagnostics Major Business
Table 30. Athena Diagnostics Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
Table 31. Athena Diagnostics Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 32. Athena Diagnostics Recent Developments/Updates
Table 33. Banyan Biomarkers Basic Information, Manufacturing Base and Competitors
Table 34. Banyan Biomarkers Major Business
Table 35. Banyan Biomarkers Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
Table 36. Banyan Biomarkers Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 37. Banyan Biomarkers Recent Developments/Updates
Table 38. Bio-Rad Laboratories Basic Information, Manufacturing Base and Competitors
Table 39. Bio-Rad Laboratories Major Business
Table 40. Bio-Rad Laboratories Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
Table 41. Bio-Rad Laboratories Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 42. Bio-Rad Laboratories Recent Developments/Updates
Table 43. Diagenic ASA Basic Information, Manufacturing Base and Competitors
Table 44. Diagenic ASA Major Business
Table 45. Diagenic ASA Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
Table 46. Diagenic ASA Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 47. Diagenic ASA Recent Developments/Updates
Table 48. Immunarray Pvt Basic Information, Manufacturing Base and Competitors
Table 49. Immunarray Pvt Major Business
Table 50. Immunarray Pvt Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
Table 51. Immunarray Pvt Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 52. Immunarray Pvt Recent Developments/Updates
Table 53. Myriad RBM Basic Information, Manufacturing Base and Competitors
Table 54. Myriad RBM Major Business
Table 55. Myriad RBM Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
Table 56. Myriad RBM Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 57. Myriad RBM Recent Developments/Updates
Table 58. Proteome Sciences Basic Information, Manufacturing Base and Competitors
Table 59. Proteome Sciences Major Business
Table 60. Proteome Sciences Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
Table 61. Proteome Sciences Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 62. Proteome Sciences Recent Developments/Updates
Table 63. ProteoSys AG Basic Information, Manufacturing Base and Competitors
Table 64. ProteoSys AG Major Business
Table 65. ProteoSys AG Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
Table 66. ProteoSys AG Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 67. ProteoSys AG Recent Developments/Updates
Table 68. Psynova Neurotech Basic Information, Manufacturing Base and Competitors
Table 69. Psynova Neurotech Major Business
Table 70. Psynova Neurotech Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
Table 71. Psynova Neurotech Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 72. Psynova Neurotech Recent Developments/Updates
Table 73. Qiagen Basic Information, Manufacturing Base and Competitors
Table 74. Qiagen Major Business
Table 75. Qiagen Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
Table 76. Qiagen Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 77. Qiagen Recent Developments/Updates
Table 78. Quanterix Corporation Basic Information, Manufacturing Base and Competitors
Table 79. Quanterix Corporation Major Business
Table 80. Quanterix Corporation Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
Table 81. Quanterix Corporation Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 82. Quanterix Corporation Recent Developments/Updates
Table 83. Thermo Fisher Scientific Basic Information, Manufacturing Base and Competitors
Table 84. Thermo Fisher Scientific Major Business
Table 85. Thermo Fisher Scientific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product and Services
Table 86. Thermo Fisher Scientific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 87. Thermo Fisher Scientific Recent Developments/Updates
Table 88. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Manufacturer (2020-2025) & (K Units)
Table 89. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue by Manufacturer (2020-2025) & (USD Million)
Table 90. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Average Price by Manufacturer (2020-2025) & (US$/Unit)
Table 91. Market Position of Manufacturers in Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2024
Table 92. Head Office and Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production Site of Key Manufacturer
Table 93. Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market: Company Product Type Footprint
Table 94. Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market: Company Product Application Footprint
Table 95. Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases New Market Entrants and Barriers to Market Entry
Table 96. Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Mergers, Acquisition, Agreements, and Collaborations
Table 97. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Region (2020-2024-2031) & (USD Million) & CAGR
Table 98. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Region (2020-2025) & (K Units)
Table 99. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Region (2026-2031) & (K Units)
Table 100. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Region (2020-2025) & (USD Million)
Table 101. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Region (2026-2031) & (USD Million)
Table 102. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Average Price by Region (2020-2025) & (US$/Unit)
Table 103. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Average Price by Region (2026-2031) & (US$/Unit)
Table 104. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Type (2020-2025) & (K Units)
Table 105. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Type (2026-2031) & (K Units)
Table 106. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Type (2020-2025) & (USD Million)
Table 107. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Type (2026-2031) & (USD Million)
Table 108. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Average Price by Type (2020-2025) & (US$/Unit)
Table 109. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Average Price by Type (2026-2031) & (US$/Unit)
Table 110. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Application (2020-2025) & (K Units)
Table 111. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Application (2026-2031) & (K Units)
Table 112. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Application (2020-2025) & (USD Million)
Table 113. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Application (2026-2031) & (USD Million)
Table 114. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Average Price by Application (2020-2025) & (US$/Unit)
Table 115. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Average Price by Application (2026-2031) & (US$/Unit)
Table 116. North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Type (2020-2025) & (K Units)
Table 117. North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Type (2026-2031) & (K Units)
Table 118. North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Application (2020-2025) & (K Units)
Table 119. North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Application (2026-2031) & (K Units)
Table 120. North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Country (2020-2025) & (K Units)
Table 121. North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Country (2026-2031) & (K Units)
Table 122. North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Country (2020-2025) & (USD Million)
Table 123. North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Country (2026-2031) & (USD Million)
Table 124. Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Type (2020-2025) & (K Units)
Table 125. Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Type (2026-2031) & (K Units)
Table 126. Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Application (2020-2025) & (K Units)
Table 127. Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Application (2026-2031) & (K Units)
Table 128. Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Country (2020-2025) & (K Units)
Table 129. Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Country (2026-2031) & (K Units)
Table 130. Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Country (2020-2025) & (USD Million)
Table 131. Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Country (2026-2031) & (USD Million)
Table 132. Asia-Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Type (2020-2025) & (K Units)
Table 133. Asia-Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Type (2026-2031) & (K Units)
Table 134. Asia-Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Application (2020-2025) & (K Units)
Table 135. Asia-Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Application (2026-2031) & (K Units)
Table 136. Asia-Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Region (2020-2025) & (K Units)
Table 137. Asia-Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Region (2026-2031) & (K Units)
Table 138. Asia-Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Region (2020-2025) & (USD Million)
Table 139. Asia-Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Region (2026-2031) & (USD Million)
Table 140. South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Type (2020-2025) & (K Units)
Table 141. South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Type (2026-2031) & (K Units)
Table 142. South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Application (2020-2025) & (K Units)
Table 143. South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Application (2026-2031) & (K Units)
Table 144. South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Country (2020-2025) & (K Units)
Table 145. South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Country (2026-2031) & (K Units)
Table 146. South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Country (2020-2025) & (USD Million)
Table 147. South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Country (2026-2031) & (USD Million)
Table 148. Middle East & Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Type (2020-2025) & (K Units)
Table 149. Middle East & Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Type (2026-2031) & (K Units)
Table 150. Middle East & Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Application (2020-2025) & (K Units)
Table 151. Middle East & Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Application (2026-2031) & (K Units)
Table 152. Middle East & Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Country (2020-2025) & (K Units)
Table 153. Middle East & Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity by Country (2026-2031) & (K Units)
Table 154. Middle East & Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Country (2020-2025) & (USD Million)
Table 155. Middle East & Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Country (2026-2031) & (USD Million)
Table 156. Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Raw Material
Table 157. Key Manufacturers of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Raw Materials
Table 158. Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Typical Distributors
Table 159. Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Typical Customers
LIST OF FIGURES
Figure 1. Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Picture
Figure 2. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue by Type, (USD Million), 2020 & 2024 & 2031
Figure 3. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Market Share by Type in 2024
Figure 4. Genome Examples
Figure 5. Proteome Examples
Figure 6. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
Figure 7. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Market Share by Application in 2024
Figure 8. Hospital Laboratories Examples
Figure 9. Research Organizations Examples
Figure 10. Others Examples
Figure 11. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value, (USD Million): 2020 & 2024 & 2031
Figure 12. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value and Forecast (2020-2031) & (USD Million)
Figure 13. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity (2020-2031) & (K Units)
Figure 14. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Price (2020-2031) & (US$/Unit)
Figure 15. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity Market Share by Manufacturer in 2024
Figure 16. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Market Share by Manufacturer in 2024
Figure 17. Producer Shipments of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases by Manufacturer Sales ($MM) and Market Share (%): 2024
Figure 18. Top 3 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Manufacturer (Revenue) Market Share in 2024
Figure 19. Top 6 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Manufacturer (Revenue) Market Share in 2024
Figure 20. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity Market Share by Region (2020-2031)
Figure 21. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value Market Share by Region (2020-2031)
Figure 22. North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031) & (USD Million)
Figure 23. Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031) & (USD Million)
Figure 24. Asia-Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031) & (USD Million)
Figure 25. South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031) & (USD Million)
Figure 26. Middle East & Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031) & (USD Million)
Figure 27. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity Market Share by Type (2020-2031)
Figure 28. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value Market Share by Type (2020-2031)
Figure 29. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Average Price by Type (2020-2031) & (US$/Unit)
Figure 30. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity Market Share by Application (2020-2031)
Figure 31. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Market Share by Application (2020-2031)
Figure 32. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Average Price by Application (2020-2031) & (US$/Unit)
Figure 33. North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity Market Share by Type (2020-2031)
Figure 34. North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity Market Share by Application (2020-2031)
Figure 35. North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity Market Share by Country (2020-2031)
Figure 36. North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value Market Share by Country (2020-2031)
Figure 37. United States Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031) & (USD Million)
Figure 38. Canada Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031) & (USD Million)
Figure 39. Mexico Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031) & (USD Million)
Figure 40. Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity Market Share by Type (2020-2031)
Figure 41. Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity Market Share by Application (2020-2031)
Figure 42. Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity Market Share by Country (2020-2031)
Figure 43. Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value Market Share by Country (2020-2031)
Figure 44. Germany Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031) & (USD Million)
Figure 45. France Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031) & (USD Million)
Figure 46. United Kingdom Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031) & (USD Million)
Figure 47. Russia Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031) & (USD Million)
Figure 48. Italy Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031) & (USD Million)
Figure 49. Asia-Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity Market Share by Type (2020-2031)
Figure 50. Asia-Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity Market Share by Application (2020-2031)
Figure 51. Asia-Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity Market Share by Region (2020-2031)
Figure 52. Asia-Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value Market Share by Region (2020-2031)
Figure 53. China Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031) & (USD Million)
Figure 54. Japan Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031) & (USD Million)
Figure 55. South Korea Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031) & (USD Million)
Figure 56. India Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031) & (USD Million)
Figure 57. Southeast Asia Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031) & (USD Million)
Figure 58. Australia Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031) & (USD Million)
Figure 59. South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity Market Share by Type (2020-2031)
Figure 60. South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity Market Share by Application (2020-2031)
Figure 61. South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity Market Share by Country (2020-2031)
Figure 62. South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value Market Share by Country (2020-2031)
Figure 63. Brazil Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031) & (USD Million)
Figure 64. Argentina Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031) & (USD Million)
Figure 65. Middle East & Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity Market Share by Type (2020-2031)
Figure 66. Middle East & Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity Market Share by Application (2020-2031)
Figure 67. Middle East & Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Quantity Market Share by Country (2020-2031)
Figure 68. Middle East & Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value Market Share by Country (2020-2031)
Figure 69. Turkey Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031) & (USD Million)
Figure 70. Egypt Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031) & (USD Million)
Figure 71. Saudi Arabia Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031) & (USD Million)
Figure 72. South Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Consumption Value (2020-2031) & (USD Million)
Figure 73. Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Drivers
Figure 74. Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Restraints
Figure 75. Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Trends
Figure 76. Porters Five Forces Analysis
Figure 77. Manufacturing Cost Structure Analysis of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases in 2024
Figure 78. Manufacturing Process Analysis of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases
Figure 79. Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Industrial Chain
Figure 80. Sales Channel: Direct to End-User vs Distributors
Figure 81. Direct Channel Pros & Cons
Figure 82. Indirect Channel Pros & Cons
Figure 83. Methodology
Figure 84. Research Process and Data Source
